HOME

Return to Table of Contents

I

MC-1 TO ELIMINATE NECROSIS AND DAMAGE IN CABG (MEND-CABG-1)

M-C Guertin, J-C Tardif
Montreal, Quebec

Nine hundred and one high-risk patients scheduled for CABG were randomly assigned to pyridoxal-5-phosphate (MC-1) (250 mg or 750 mg/day) or placebo beginning 3-10 hours prior to surgery and continued to postoperative day 30. In high-risk patients undergoing CABG, treatment with pyridoxal-5-phosphate (MC-1) is associated with a significant reduction in perioperative myocardial infarction with CK-MB ³100 ng/mL.
RESULTS: At 30 days after CABG, MC-1 250 mg (compared with placebo) reduced the composite of death, non-fatal cerebral infarction, and non-fatal MI by 14.0% (p=0.3124) with peak CK-MB ³50 ng/mL; 32.3% (p=0.0349) with peak CK-MB ³70 ng/mL; and 37.2% (p=0.0283) with peak CK-MB ³100 ng/mL. Compared with placebo, MC-1 250 mg reduced MIs with peak CK-MB ³50 ng/mL by 15.2% (p=0.2988), MIs with peak CK-MB ³70 ng/mL by 37.6% (p=0.0192), and MIs with peak CK-MB ³100 ng/mL by 47.2% (p=0.0083).

PREVIOUS     NEXT